Aperio Group LLC lifted its holdings in CVS Health Corp (NYSE:CVS) by 8.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 813,347 shares of the pharmacy operator’s stock after purchasing an additional 60,058 shares during the quarter. Aperio Group LLC owned 0.08% of CVS Health worth $66,141,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in CVS. Fieldpoint Private Securities LLC raised its position in CVS Health by 333.3% during the second quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after acquiring an additional 1,000 shares in the last quarter. Arcadia Investment Management Corp MI raised its position in CVS Health by 119.6% during the third quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after acquiring an additional 726 shares in the last quarter. MPS Loria Financial Planners LLC bought a new stake in CVS Health during the second quarter worth $119,000. Gemmer Asset Management LLC raised its position in CVS Health by 15.3% during the second quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock worth $121,000 after acquiring an additional 200 shares in the last quarter. Finally, Captrust Financial Advisors bought a new stake in CVS Health during the second quarter worth $155,000. 81.63% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Corp (NYSE CVS) opened at $73.41 on Tuesday. The company has a market cap of $74,363.75, a PE ratio of 15.17, a PEG ratio of 1.38 and a beta of 0.89. The company has a quick ratio of 0.55, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. CVS Health Corp has a fifty-two week low of $66.45 and a fifty-two week high of $84.72.

CVS Health (NYSE:CVS) last posted its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.01. The firm had revenue of $46.18 billion during the quarter, compared to analysts’ expectations of $46.17 billion. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.64 earnings per share. equities research analysts forecast that CVS Health Corp will post 5.9 EPS for the current fiscal year.

In related news, EVP Lisa Bisaccia sold 29,445 shares of the firm’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total value of $2,208,375.00. Following the completion of the transaction, the executive vice president now owns 15,556 shares in the company, valued at approximately $1,166,700. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Thomas M. Moriarty sold 20,547 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $81.17, for a total transaction of $1,667,799.99. Following the completion of the transaction, the executive vice president now owns 43,178 shares of the company’s stock, valued at approximately $3,504,758.26. The disclosure for this sale can be found here. 0.61% of the stock is owned by company insiders.

Several equities analysts have commented on CVS shares. Jefferies Group set a $76.00 price objective on shares of CVS Health and gave the company a “hold” rating in a report on Monday, December 4th. Royal Bank of Canada started coverage on shares of CVS Health in a report on Tuesday, September 19th. They issued an “outperform” rating and a $95.00 price objective on the stock. Robert W. Baird reiterated a “hold” rating and issued a $77.00 price objective on shares of CVS Health in a report on Friday, October 27th. Leerink Swann set a $85.00 price objective on shares of CVS Health and gave the company a “buy” rating in a report on Monday, December 4th. Finally, Citigroup set a $76.00 price objective on shares of CVS Health and gave the company a “hold” rating in a report on Monday, December 4th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $86.35.

ILLEGAL ACTIVITY WARNING: “Aperio Group LLC Increases Stake in CVS Health Corp (CVS)” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://theolympiareport.com/2017/12/26/aperio-group-llc-increases-stake-in-cvs-health-corp-cvs.html.

CVS Health Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.